Neuphoria Therapeutics (NEUP) Balance Sheet: Assets & Liabilities

Neuphoria Therapeutics (NEUP) Balance Sheet

As of Jun 30, 2026 (end of fiscal 2026), Neuphoria Therapeutics reported total assets of AUD 28.71B and total liabilities of AUD 4.11B. Shareholders' equity was AUD 24.60B, up 85102.2% from AUD 28.87M a year earlier. Total debt stood at AUD 34.34K against AUD 19.87B in cash and short-term investments, a net cash position of AUD 19.87B. That puts debt-to-equity at 0.00, compared with 0.01 a year earlier.

Neuphoria Therapeutics Balance Sheet Analysis

Values in billions AUD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Neuphoria Therapeutics Inc. (NEUP) - Annual data in billions AUD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jun 2017
Current Assets
Cash and Cash Equivalents	19.87	0.02	0.01	0.01	0.02	0.02	0.00	0.01	0.02	0.03
Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	19.87	0.02	0.01	0.01	0.02	0.02	0.00	0.01	0.02	0.03
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	1.20	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.00
Total Current Assets	21.07	0.02	0.01	0.01	0.03	0.02	0.01	0.02	0.03	0.04
Non-Current Assets
Property, Plant & Equipment (Net)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	3.50	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Intangible Assets	4.14	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Other Non-Current Assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Non-Current Assets	7.64	0.02	0.01	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Total Assets	28.71	0.04	0.03	0.03	0.04	0.04	0.02	0.04	0.05	0.06
Current Liabilities
Accounts Payable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Short-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.01
Accrued Liabilities	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-
Deferred Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Liabilities	0.76	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Current Liabilities	0.76	0.01	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01
Non-Current Liabilities
Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01
Deferred Tax Liabilities	0.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Non-Current Liabilities	3.00	0.01	0.01	0.00	0.00	0.00	0.00	0.01	0.01	0.01
Total Non-Current Liabilities	3.35	0.01	0.01	0.00	0.00	0.00	0.01	0.02	0.03	0.02
Total Liabilities	4.11	0.01	0.01	0.01	0.01	0.00	0.01	0.03	0.04	0.03
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.15	0.14	0.10	0.10	0.10	0.10
Retained Earnings	-191.80	-0.27	-0.18	-0.16	-0.12	-0.12	-0.10	-0.10	-0.10	-0.08
Accumulated Other Comprehensive Income	-2.06	-2.85	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	218.46	200.19	0.20	0.19	0.00	0.00	0.00	0.00	0.00	0.00
Shares Outstanding	0.01	-	0.20	1.47	1.35	1.01	-	-	-	-
Total Stockholders' Equity	24.60	0.03	0.02	0.02	0.04	0.04	0.01	0.01	0.01	0.03
Total Liabilities & Equity	28.71	28.59	0.03	0.03	0.04	0.04	0.02	0.04	0.05	0.06

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Neuphoria Therapeutics Balance Sheet

How much debt does Neuphoria Therapeutics have?

Neuphoria Therapeutics had total debt of AUD 34.34K as of Jun 30, 2026, against AUD 19.87B in cash and short-term investments. Its debt-to-equity ratio was 0.00. Total debt was AUD 226.49K a year earlier.

What are Neuphoria Therapeutics's total assets?

Neuphoria Therapeutics reported total assets of AUD 28.71B as of Jun 30, 2026, up 65990.3% from AUD 43.44M a year earlier. Total liabilities were AUD 4.11B.

What is Neuphoria Therapeutics's shareholders' equity?

Neuphoria Therapeutics's shareholders' equity was AUD 24.60B as of Jun 30, 2026, or about AUD 4546.02 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition